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Abstract 
Advanced hepatocellular carcinoma still represents an unmet medical need that has only a 
limited overall survival despite the introduction of the multi-kinase inhibitor sorafenib. Re-
cently, inhibitors of histone and other protein deacetylases have been established as novel 
therapeutic approaches to cancer diseases. We here review the molecular rationale for 
combining  these  two  novel  targeted  therapies  and  report  a  patient  with  metastasized 
hepatocellular carcinoma who showed a partial remission of primary and metastatic lesions 
for  five  months  after  a  combination  therapy  with  sorafenib  and  the  orally  available 
pan-deacetylase inhibitor panobinostat. 
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Introduction 
Hepatocellular  carcinoma  (HCC)  is  the  most 
common primary tumor of the liver and represents 
the 2nd and 5th most common cause of cancer related 
death  in  men  and  women,  respectively, 
worldwide[1-2]. HCC also shows rising incidence and 
mortality rates in Western countries due to the high 
prevalence  of  chronic  viral  hepatitis,  alcoholic  liver 
diseases and steatoheaptitis[3-5].  
Although  several  molecular  alterations  have 
been  identified  in  HCC[2,  6],  so  far  only  the  mul-
ti-kinase  inhibitor  sorafenib  proved  a  significant 
treatment  advantage  in  liver  cancer[7],  while  other 
targeted therapies like small molecule receptor tyro-
sine kinase inhibitors or monoclonal anti-growth fac-
tor (receptor) antibodies failed[8]. As sorafenib therapy 
is associated with high treatment costs[9] and still un-
satisfying  overall  response  rates[8],  novel  further 
treatment approaches are urgently needed.  
Inhibitors of histone deacetylases (HDAC) have 
been established as potent novel anticancer therapies 
in hematologic and solid tumors[10-12]. We have shown 
previously  that  expression  of  HDAC  isoenzymes  is 
associated  with  overall  survival  in  HCC  patients[13] 
and  that  various  HDAC  inhibitors  can  induce  cell 
death and synergize with chemotherapeutics in HCC 
models[14-16].  Panobinostat  (LBH589)  is  a  novel  oral 
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pan-deacetylase  inhibitor  that  has  shown  strong 
pro-apoptotic  and  anti-proliferative  effects  in  HCC 
cell lines and a xenograft model[17] and is currently 
under investigation for various tumor entities[18-19]. 
Classically,  deacetylase  inhibitors  (DACi)  are 
considered  to  modulate  the  transcriptional  control 
(Figure 1) of various genes by interfering with HDAC 
isoforms in the nucleus and thus control chromatin 
packing  and  conformation,  leading  to  either  an 
“opened” and transcriptionally active or “closed” and 
transcriptionally suppressed DNA structure[10]. Here, 
a strong role for the p53-dependent regulation of the 
endogenous  cell  cycle  inhibitor  p21cip1/waf1  has  been 
described for various DACi like  panobinostat, vori-
nostat  and  others[20].  Recently,  experimental  data 
suggests  that  also  regulatory  miRNAs  are  strongly 
influenced by DACi and that this contributes signifi-
cantly  to  the  observed  changes  in  gene 
expression[21-23]. Our own preclinical data also indicate 
that  pan-DACi  like  panobinostat  also  influence  the 
acetylation  status  of  a  variety  of  cytosolic  and 
non-histone proteins[24], although the acetylome is still 
not  well  defined[25].  This  could  affect  the  protein 
folding  and  function  of  several  so  far  unidentified 
proteins  leading  to  the  activation  of  the  unfolded 
protein  response,  ER  stress-mediated  apoptosis  and 
autophagy  as  alternative  mechanisms  of  cell  death 
execution[17, 26-27]. The influence of pan-DACi on cel-
lular  protein  stability  and  function  has  also  been 
demonstrated  to  be  involved  in  the  known  an-
ti-angiogenic effects of panobinostat, e.g. by destabi-
lizing  the  hypoxia  sensor  Hif-1[28]  and  we  have 
shown previously in a xenograft mouse model that 
panobinostat leads to a significan reduction in tumor 
vascularization[17]. DACi can further influence signal 
transduction  pathways  related  to  angiogenesis  by 
modulating  the  expression  of  growth  factors  like 
VEGF[29] or of downstream kinases like mitogen acti-
vated protein kinases (MAPK) [17, 30-31]. 
 
 
Figure 1. Molecular pathways affected by panobinostat and sorafenib. Besides the classical effects of HDACi on transcriptional regulators 
(e.g. p53, miRNAs, HDAC) and the regulation of p21cip1/waf1 expression, panobinostat is also capable to induce canonical (death-receptor 
and mitochondria related) and alternative cell death pathways (e.g. ER stress, unfolded protein response and autophagy). Although the 
effects of deacetylase inhibitors on protein folding and function are not completely understood, the inhibition of non-nuclear HDAC 
enzymes influences protein stability and enzymatic activity of various cellular proteins, including the destabilization of the hypoxia sensor 
Hif-1 and the function of different protein kinases. In addition, the expression of these proteins can also be affected via the shown 
influence on transcriptional control processes. The multi-kinase inhibitor sorafenib is predominantly inhibiting the RAS-RAF-MAPK 
pathway and thus inhibits processes related to angiogenesis, proliferation and survival. Together, both compounds synergize at the level 
of protein kinases and their downstream effectors leading to inhibition of tumor growth.  Journal of Cancer 2012, 3 
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Signaling via protein kinase cascades is a hall-
mark of tumor cell proliferation, survival and cancer 
related angiogenesis. Monoclonal antibodies against 
pro-angiogenic  growth  factor  receptors  (e.g.  bevaci-
zumab)  as  well  as  small  molecule  kinase  inhibitors 
(e.g.  everolimus,  sorafenib)  targeting  downstream 
signal transduction molecules have recently been in-
troduced into treatment regimes for various advanced 
solid  tumors.  Sorafenib  has  been  approved  for  the 
treatment of advanced stages of HCC and inhibits the 
RAF-Erk-MAPK signaling in tumor cells as well as in 
endothelial  cells,  thus  exerting  a  dual  effect  on  cell 
viability,  proliferation  and  angiogenesis[32-33].  Inhibi-
tion of survival pathways by sorafenib has now been 
shown to lead to cell death via autophagy induction, 
too,  and  several  studies  also  showed  a  synergism 
when combined with DACi[34-37]. Recently, the com-
bination  of  panobinostat  and  sorafenib  has  been 
shown  to  exert  additive  anti-proliferative  and 
pro-apoptotic effects in HCC cell culture and xeno-
graft models[38]. The following model of action for this 
combination is suggested (Figure 1): DACi and kinase 
inhibitors  synergize  at  the  level  of  protein  kinases, 
modulating these central tumorigenic pathways. In-
hibition of DAC modulates protein kinase expression 
and activity and shifts the cellular microenvironment 
towards cell death induction which is then addition-
ally hit by the kinase inhibition. 
We therefore initiated a trial with the standard 
dose of sorafenib (800 mg daily) and a dose-escalation 
of panobinostat starting at 20 mg on day 1 and day 4 
for 2 weeks and sorafenib alone in week 3. This cycle 
was repeated until disease progression or withdrawal 
of informed consent. The trial was approved by the 
local ethics committee of the University Hospital Er-
langen,  Germany,  and  is  registered  at  clinicaltri-
als.gov (NCT00823290). 
We  here  report  a  case  of  advanced  metastatic 
HCC treated with the standard dose of sorafenib and 
the  oral  pan-deacetylase  inhibitor  panobinostat, 
which  could  provide  a  novel  treatment  option  for 
advanced HCC. 
Case Report 
A  68-year  old  man  was  diagnosed  with  ad-
vanced multilocular HCC on the basis of ethyltoxic 
liver cirrhosis (Child-Pugh A) in September 2009. At 
the  time  of  diagnosis,  a  moderately  differentiated 
metastasis to the thyroid gland and several metastases 
to the autochthonic spine musculature and the verte-
bral bodies with stenoses of the spinal canal (L I) and 
the neuroforamina (Th XII to L I) were present (Figure 
2).  
 
Figure 2. Baseline radiologic assessment of the patient in Sep-
tember 2009 before initiation of sorafenib therapy. A: sonography 
showing a 10 cm lesion in the liver. B: Magnetic resonance imaging 
(MRI) of the liver revealing a large lesion in the right liver lobe and 
several diffuse smaller nodules in the total liver. C: MRI scan of the 
soft tissue metastasis in the autochthonic spine musculature. 
 
Therapy with sorafenib at 800 mg per day was 
started in September 2009 and showed a  mixed re-
sponse in MRI scan 6 weeks after treatment start with 
partly necrotic or decreased lesions but also increas-
ing and novel lesions in the liver and stable soft tissue 
and  bone  metastases.  Sonography  revealed  a  large 
lesion (11 cm) in the right liver lobe which was more 
than 75% necrotic but also 8 additional lesions up to 5 
cm (Figure 3).  Journal of Cancer 2012, 3 
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Figure 3. Staging after sorafenib monotherapy and before initia-
tion of additional panobinostat treatment. A: Contrast enhanced 
(left) and native sonography (right) showing necrosis (> 75%) in 
the largest lesion. B: MRI scan of the liver showing a mixed radi-
ologic response compared to baseline. C: MRI scan of the soft 
tissue metastasis. 
 
After obtaining informed consent, therapy with 
panobinostat  was  started  in  November  2009:  soraf-
enib was continued at 800 mg daily and panobinostat 
at 20 mg was administered orally on days 1 and 4 for 
two consecutive weeks followed by one week of so-
rafenib  therapy  alone,  representing  a  three  week 
therapy cycle which was repeated 5 times.  
Staging was performed after three cycles in Jan-
uary 2010 (Figure 4). Here, contrast enhanced sonog-
raphy showed constant lesions in liver segments V, VI 
and VII (94*80*75 mm) as well as in segment II (29*32 
mm) with signs of cirrhosis but no ascites. MRI scan-
ning showed slightly decreasing hemorrhagic lesions 
with signs of liquid transformation in both liver lobes 
and of the soft tissue metastasis in the autochthonic 
spine musculature. No new lesions were discovered. 
The  patient  reported  diarrhea,  exsiccosis,  hy-
pocalcaemia  and  nausea  during  the  last  cycle  that 
responded to supportive treatment. 
 
 
 
Figure  4.  Staging after 8 weeks of sorafenib and panobinostat 
combination  therapy.  A:  Contrast  enhanced  (left)  and  native 
sonography (right). B: MRI scan of the liver. C: MRI scan of the soft 
tissue metastasis.  Journal of Cancer 2012, 3 
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After eight cycles of sorafenib and panobinostat, 
MRI staging in April 2010 showed a further regression 
of the lesions in the liver and the spine musculature. 
Contrast  sonography  showed  a  necrotic  lesion  in 
segment VI and a hypervascularized but still constant 
lesion on segment VIII. 
By request of the patient the therapy with pano-
binostat was stopped in May 2010 as the patient ex-
perienced lack of appetite and slight weight loss (3 kg 
since  February  2010),  which  was  perceived  as  in-
creasingly wearing by the patient and lead to with-
drawal of consent. Sorafenib was further continued at 
the standard dose. 
Although transaminases and -GT were initially 
elevated (maximum GOT 130 U/l, GPT 178 U/l, -GT 
167 U/l), these parameters rapidly normalized under 
sorafenib  therapy  and  stayed  in  the  normal  range 
until the end of treatment with panobinostat (Figure 
5A).  Albumin  and  prothrombin  time  as  markers  of 
liver  synthesis  capacity  were  slightly  decreased 
throughout  the  treatment  period  without  signs  of 
clinical symptoms. Interestingly, the initially elevated 
tumor marker -fetoprotein (AFP) returned to normal 
values already under sorafenib therapy despite a lack 
of radiologic response at this stage (Figure 5B). AFP 
levels remained below 10 ng/ml until the end of the 
panobinostat treatment period, too, but raised to 36.6 
ng/ml at the end of the observation period. This in-
crease in AFP was also paralleled by an increase in 
transaminases and -GT at this stage indicating a de-
terioration of liver function and progress of the tumor 
disease  under  sorafenib  monotherapy.  Hematologic 
assessment  revealed  leucopenia,  low  hemoglobin, 
erythrocytes  and  hematocrit  under  initial  sorafenib 
therapy.  These  values  remained  stable  also  under 
additional  panobinostat  therapy  with  even  an  ame-
lioration  of  leucopenia  to  normal  range  after  three 
cycles.  Differential  blood  count  showed  a  stably 
lymphopenia and  monocytosis during 
the  whole  treatment  period.  All  other 
laboratory parameters remained in the 
normal  range  throughout  the  study 
period. 
 
 
 
Figure  5.  Time  course  of  transaminases  and 
AFP  under  sorafenib  and  panobinostat  treat-
ment. (A) Serum levels of GOT, GPT and -GT 
remained in the normal range under panobino-
stat (< 50 U/l for GOT and GPT, < 60 U/l for 
-GT) but rapidly increased again after cessation 
of panobinostat intake. (B) The tumor marker 
-fetoprotein (AFP) decreased under the com-
bination therapy with sorafenib and panobinostat 
but  rised  again  under  sorafenib  monotherapy 
(normal level < 10 ng/ml). Panobinostat treat-
ment period is indicated in the figure. 
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Discussion 
We here report the first case of a combination 
therapy of the multikinase inhibitor sorafenib with the 
oral pan-deacetylase inhibitor panobinostat in a pa-
tient with advanced metastasized hepatocellular car-
cinoma.  
Sorafenib  has  been  established  as  the  first-line 
therapy  for  advanced  HCC[7].  Yet,  the  overall  re-
sponse  rate  still  remains  unsatisfying  with  only 
around  3%[8].  Typically,  sorafenib  induces  a  stable 
disease  in  the  majority  of  patients.  Our  patient  ini-
tially showed a mixed response to sorafenib as a sin-
gle agent with some lesions showing a radiologic re-
sponse while other lesions increased in size or even 
appeared anew. The add-on therapy with 20 mg of the 
pan-deacetylase panobinostat further ameliorated the 
clinical situation. Besides beneficial effects on tumor 
burden, no additional hematologic or serologic toxici-
ties were observed, indicating a good tolerability of 
the  combination  therapy  in  patients  with  advanced 
HCC  but  early  stage  cirrhosis  (Child-Pugh  A).  The 
serologic assessment of transaminases, -GT and AFP 
showed a quick and significant response of the patient 
to both, the initial sorafenib treatment and the addi-
tion of panobinostat, and thus confirmed the current 
concept of AFP as a predictive biomarker for HCC[39]. 
Our findings also confirm the pivotal role of selecting 
adequate imaging techniques for assessing treatment 
response[40]. 
Several preclinical studies report additive effects 
between multikinase inhibitors and inhibitors of his-
tone  and  other  protein  deacetylases.  Our  own  data 
with panobinostat in HCC cell lines and a xenograft 
model show an inhibition of proliferation pathways 
via upregulation of the endogenous cell cycle inhibi-
tor  p21cip1/waf1,  a  classical  target  of  HDAC 
inhibitors[20], but independent of growth factor related 
kinases[17]. Yet, panobinostat was also capable of in-
hibiting  MAPK  signaling  under  these  experimental 
conditions.  Interestingly,  MAPK  is  also  the  final 
downstream target of receptor tyrosine kinases and 
the  Ras-Raf  signaling  pathway,  which  is  the  main 
target of sorafenib[41]. The dual blockade of cell cycle 
progression could thus represent a molecular basis for 
the observed potent effects of the combination thera-
py. 
The  synergism  between  sorafenib  and  histone 
deacetylase inhibitors has been proposed to be also 
mediated by the activation of CD95-mediated extrin-
sic  apoptotic  pathways[35,  42-43].  Additionally,  pano-
binostat is also capable of inducing cell death in liver 
cancer models by activating alternative pathways of 
apoptosis  induction,  e.g.  via  activation  of  ER  stress 
and  autophagy  mechanisms[17,  24].  Interestingly,  also 
sorafenib has recently been demonstrated to activate 
autophagy and ER stress mechanisms in various set-
tings[36-37, 44]. Several papers now reported a synergism 
in inducing these alternative cell death mechanisms 
by a combination of sorafenib and histone deacetylase 
inhibitors[34-35, 43].  
These  preclinical  findings  and  experimental 
models provide a clear rationale for the good clinical 
tolerability and efficacy of the combination of soraf-
enib and panobinostat: both compounds lead to cell 
cycle  arrest  and  proliferation  inhibition  via  two  in-
dependent pathways and both compounds can induce 
cell death by interacting with classical apoptosis sig-
naling as well as alternative forms of cell death like 
autophagy.  Additional  effects  of  deacetylase  inhibi-
tors  like  inhibition  of  angiogenesis[17,  31]  can  further 
contribute  to  these  additive  effects  here.  Yet,  these 
models need to be further investigated, esp. in clinical 
settings. Recently, the oral HDAC inhibitor resmino-
stat  also  showed  a  favourable  pharmacokinetic  and 
safety profile in a phase I/II trial in patients with ad-
vanced and sorafenib-resistant HCC[45]. 
In  summary,  this  case  report  demonstrates  a 
good tolerability and efficacy of a combination ther-
apy of sorafenib and panobinostat in a patient with 
HCC that needs to be evaluated further in additional 
clinical trials, also to identify the discussed molecular 
pathways of this treatment option. 
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